Acute intermittent porphyria in adults: a clinical case

Background. Porphyria unites genetic pathologies related to abnormal haem (an intermediate product of haemoglobin metabolism) synthesis and its toxic products accumulation in human body. Symptoms can vary, from photosensitivity, skin rashes and chronic abdominal pain towards partial or complete paralysis and acute psychosis. This metabolic disorder is diagnosed with molecular genetic and laboratory biosample tests. Drug therapy aims at reducing toxic metabolites concentration in patient’s blood.

Clinical Case Description. A 28-yo female patient had an acute atypical porphyria attack with a later onset of neurovisceral manifestations (acute abdominal pain, tachycardia) progressing post-drug-treatment into acute sensorimotor polyneuropathy with flaccid, predominantly proximal, hands-prevalent tetraparaesis. Biochemical urine tests at the National Research Center for Hematology (by 30.06.2020) revealed porphobilinogen 55.3 mg/L at norm <3. Vital indications required an urgent haem arginate pathogenetic therapy (Normosang) in a 4-day course of 3 mg/kg/day drop infusion. The recommended course was well tolerated. Drug therapy and rehabilitation entailed a positive dynamics of restoring limb muscle strength towards an almost easy getting-up from chair and bed, and skin lightening. The patient was discharged on day 20 with diagnosis: “Acute intermittent porphyria. Axonal-demyelinating sensorimotor polyneuropathy. Severe flaccid asymmetric predominantly proximal hands-prevalent tetraparaesis. Subacute course, stabilisation phase. Condition after one course of haem arginate pathogenetic therapy (Normosang) at 3 mg/kg/day”. A resident haematologist surveillance was recommended, with a routine referral for inpatient examination and treatment at the Department of Orphan Diseases of the National Research Center for Hematology, Ministry of Health of Russia.

Conclusion. Porphyria is relatively rarely diagnosed, about 12 cases per 100,000 people. The symptoms variety and nonspecificity conduce to a low detection rate, and untimely diagnoses can entail severe clinical manifestations, including lethal outcomes.

1. Stölzel U., Doss M.O., Schuppan D. Clinical Guide and Update on Porphyrias. Gastroenterology. 2019; 157(2): 365–381.e4. DOI: 10.1053/j.gastro.2019.04.050

2. García-Diz L., Murcia M.A., Gris J.L., Pons A., Monteagudo C., Martínez-Tomé M., JiménezMonreal A.M. Assessing nutritional status of acute intermittent porphyria patients. Eur. J. Clin. Invest. 2012; 42(9): 943–952. DOI: 10.1111/j.1365-2362.2012.02673.x

3. Yasuda M., Chen B., Desnick R.J. Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/ causative genes. Mol. Genet. Metab. 2019; 128(3): 320–331. DOI: 10.1016/j.ymgme.2018.11.012

4. Sheikh A.A.E., Sheikh A.B., Sagheer S., Tariq U., Bukhari M.M., Fatima Z., Afzal R.M. Acute Intermittent Porphyria: A Rare Cause of Acute Disseminated Encephalomyelitis. Cureus. 2018; 10(7): e2989. DOI: 10.7759/cureus.2989

5. Stölzel U., Stauch T., Kubisch I. Porphyrien [Porphyria]. Internist (Berl). 2021; 62(9): 937–951. German. DOI: 10.1007/s00108-021-01066-1

6. Stein P., Badminton M., Barth J., Rees D., Stewart M.F.; British and Irish Porphyria Network. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. Ann. Clin. Biochem. 2013; 50(Pt 3): 217–223. DOI: 10.1177/0004563212474555

7. Ricci A., Di Pierro E., Marcacci M., Ventura P. Mechanisms of Neuronal Damage in Acute Hepatic Porphyrias. Diagnostics (Basel). 2021; 11(12): 2205. DOI: 10.3390/diagnostics11122205

8. Anyaegbu E., Goodman M., Ahn S.Y., Thangarajh M., Wong M., Shinawi M. Acute intermittent porphyria: a diagnostic challenge. J. Child. Neurol. 2012; 27(7): 917–921. DOI: 10.1177/0883073811427603

9. Lin C.S., Lee M.J., Park S.B., Kiernan M.C. Purple pigments: the pathophysiology of acute porphyric neuropathy. Clin. Neurophysiol. 2011; 122(12): 2336-2344. DOI: 10.1016/j.clinph.2011.07.036

10. de Souza P.VS., Badia B.M.L., Farias I.B., Pinto W.B.V.R., Oliveira A.S.B. Acute Hepatic Porphyria: Pathophysiological Basis of Neuromuscular Manifestations. Front. Neurosci. 2021; 15: 715523. DOI: 10.3389/fnins.2021.715523

11. Karakulova I.V., Selianina N.V., Zhelnin A.V., Nekrutenko L.A., Sosnin D. Yu., Seksyaev N.E., Chalova E.A. A rare case of neurological manifestations of acute intermittent porphyria. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019; 119(1): 72–75 (In Russ., English abstract). DOI: 10.17116/jnevro201911901172

12. Tchaikovskii V., Desnick R.J., Bishop D.F. Molecular expression, characterization and mechanism of ALAS2 gain-of-function mutants. Mol. Med. 2019; 25(1): 4. DOI: 10.1186/s10020-019-0070-9

13. Kornilova T.Yu., Tadzhieva V.D., Iglina M.A., Semenova N.L., Vasilchev A.V., Savina I.E. Acute intermittent porphyria as a cause of maternal mortality (case report). Ul’yanovskii mediko-biologicheskii zhurnal. 2017; 4: 83–90 (In Russ., English abstract). DOI: 10.23648/UMBJ.2017.28.8744

14. Smagina I.V., Yurchenko Yu.N., Mersiyanova L.V., Elchaninova S.A., Elchaninov D.V. Challenges in diagnosis of nervous system impairment in porphyria. Neurological Journal. 2016; 21(5): 299–304 (In Russ., English abstract). DOI: 10.18821/1560-9545-2016-21-5-299-304

15. Zagidullina K.L., Popova N.A., Astashina E.E. Difficulties of diagnosing acute intermittent porphyria in clinical practice. Kazanskii meditsinskii zhurnal. 2016; 97(6): 975–978 (In Russ., English abstract). DOI: 10.17750/KMJ2016-975

16. Popov A.A., Mironov V.A., Volkova L.I., Tregubov K.A., Belov S.S., Mokretsov S.I., Gabidullin T.I. Acute intermittent porphyria. Trudnyi patsient. 2021; 19(5): 43-44 (In Russ., English abstract). DOI: 10.224412/2074-1005-2021-5-43-47